在帕金森病中,中皮层临网络的形态变化与冲动控制障碍的帕金森病
Mohammed Farhan Ansari1, Shweta Prasad2, Sujas Bhardwaj1
1Department of Neurology, National Institute of Mental Health and Neurosciences (NIMHANS), Hosur Road, Bangalore, Karnataka, 560029, India.
Journal of neural transmission (Vienna, Austria : 1996)
|January 12, 2024
概括
帕金森病 (PD) 中的冲动控制障碍与大脑变化有关. 具体来说,患有PD和ICD的患者表现出额头极大小的减少,这表明中皮层临网络的作用.
科学领域:
- 神经科学是一个神经科学.
- 神经学 神经学
- 放射学 放射学是指放射学
背景情况:
- 冲动控制障碍 (ICD) 是帕金森病 (PD) 中显著的非运动症状.
- 中皮层临网络与奖励处理和执行功能有关,可能在PD相关的ICD中发挥作用.
研究的目的:
- 在帕金森病患者中,与没有ICD (PD-ICD) 和健康对照者 (HC) 相比,研究带有ICD (PD+ICD) 的帕金森病患者中,在中皮层临床网络内的形态变化.
主要方法:
- 使用3T磁力共振成像来评估18名PD+ICD患者,19名PD-ICD患者和19名HC患者的皮层厚度和皮下体积.
- 聘用FreeSurfer进行神经成像分析,专注于中皮层和临网络区域.
- 在PD-Rating Scale (QUIP-RS) 中使用冲动强迫障碍问卷诊断的ICD.
主要成果:
- 与HC相比,PD+ICD患者表现出左前极缩,与PD-ICD患者相比,显著性的趋势.
- 在PD+ICD和PD-ICD组之间没有发现疾病持续时间或多巴胺作用药物的显著差异.
- 在PD+ICD组中,QUIP-RS得分与左尾状体积之间观察到负相关性.
结论:
- 帕金森病患者与ICD显示出明显的形态变化在 mesocorticolimbic 系统.
- 这些结构变化,特别是在左前极,可能是PD中ICD的发展或表现的基础.
相关概念视频
01:37Neural Regulation
39.4K
Digestion begins with a cephalic phase that prepares the digestive system to receive food. When our brain processes visual or olfactory information about food, it triggers impulses in the cranial nerves innervating the salivary glands and stomach to prepare for food.
39.4K
01:24Parkinson's Disease: Treatment
272
Neurodegenerative disorders, such as Parkinson's Disease (PD), involve the gradual and irreversible destruction of neurons in particular brain areas. These disorders exhibit standard features like proteinopathies, selective vulnerability of some neurons, and an interaction of intrinsic properties, genetics, and environmental influences in neural injury.
Parkinson's Disease is primarily a result of the loss of dopaminergic neurons in the substantia nigra pars compacta. The cornerstone of...
Parkinson's Disease is primarily a result of the loss of dopaminergic neurons in the substantia nigra pars compacta. The cornerstone of...
272
01:15Parkinson's Disease: Overview
551
Neurodegenerative disorders are progressive diseases that cause irreversible damage and loss to neurons in specific brain areas. Examples of these disorders include Parkinson's disease, Alzheimer's disease, Multiple Sclerosis (MS), and Amyotrophic Lateral Sclerosis (ALS). These disorders share characteristics such as proteinopathies, selective neuronal vulnerability, and a complex interplay between genetic and environmental factors. The primary therapeutic goal for these conditions is...
551